Head-To-Head Comparison: Editas Medicine (NASDAQ:EDIT) versus Kymera Therapeutics (NASDAQ:KYMR)

Editas Medicine (NASDAQ:EDIT) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Volatility and Risk

Editas Medicine has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Profitability

This table compares Editas Medicine and Kymera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-340.96%	-80.13%	-50.99%
Kymera Therapeutics	-191.26%	-24.96%	-20.27%

Earnings and Valuation

This table compares Editas Medicine and Kymera Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$78.12 million	2.36	-$153.22 million	($2.56)	-0.87
Kymera Therapeutics	$87.56 million	32.29	-$146.96 million	($2.34)	-18.65

Kymera Therapeutics has higher revenue and earnings than Editas Medicine. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.9% of Editas Medicine shares are held by institutional investors. 1.9% of Editas Medicine shares are held by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Editas Medicine and Kymera Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1	6	6	0	2.38
Kymera Therapeutics	0	4	12	1	2.82

Editas Medicine presently has a consensus target price of $7.92, suggesting a potential upside of 255.01%. Kymera Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 22.57%. Given Editas Medicine’s higher possible upside, equities analysts clearly believe Editas Medicine is more favorable than Kymera Therapeutics.

Summary

Kymera Therapeutics beats Editas Medicine on 12 of the 15 factors compared between the two stocks.

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.